BeiGene’s Tislelizumab Improves Survival in Esophageal Cancer Study

BeiGene continues its roll with anti-PD-1 monoclonal antibody tislelizumab, announcing topline data yesterday from its fourth positive Phase III trial, this time in esophageal squamous cell carcinoma (ESCC).